Trial Profile
A Phase II Study of Lorlatinib (PF-06463922) in Advanced Anaplastic Lymphoma Kinase (ALK) and ROS Proto-Oncogene 1 (ROS1) Rearranged Non-Small Cell Lung Cancer (NSCLC) With Central Nervous System (CNS) Metastasis in the Absence of Measurable Extracranial Lesions
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Mar 2021 Planned primary completion date changed from 1 May 2021 to 1 Jan 2022.
- 19 Aug 2020 Planned End Date changed from 1 Mar 2023 to 1 May 2023.
- 19 Aug 2020 Planned primary completion date changed from 1 Mar 2020 to 1 May 2021.